BEIJING, SHANGHAI and BOSTON, Jan. 6, 2025 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been…
The Registrational Clinical Data of Glecirasib was Published in Nature Medicine
BEIJING, SHANGHAI and BOSTON, Jan. 6, 2025 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been…
